About this Journal Submit a Manuscript Table of Contents

The Actual Value of Molecular Imaging in the Assessment of the Disease Relapse of Prostate Cancer

Call for Papers

About 40% of all patients undergoing radical treatment for localized prostate cancer develop biochemical relapse during lifetime, but only 10-20% of them will show clinically detectable recurrences. It is particularly difficult to discriminate between local relapse and bone or nodal metastases and to decide who the patients that should be investigated and treated are.

Currently, most of the patients receive androgen deprivation therapy or salvage radiotherapy soon after PSA relapse and without any effort to localize the origin of the relapse. In fact, current imaging techniques have some potential, but too many limits are yet encountered. Nowadays, new molecular imaging modalities, such as dynamic MRI and PET/CT, are evolving in this setting, and pioneering salvage approaches are emerging.

We invite the authors to contribute with original research papers and reviews on this important topic that may involve urological as well as radiological expertise. We are particularly interested in papers describing the new and emerging molecular imaging modalities in the assessment of prostate cancer relapse. Potential topics include, but not limited to:

  • Elucidating the risk factors of disease relapse of prostate cancer after radical treatment
  • Assessing the potentials and limits of conventional imaging techniques in the identification of local or systemic relapse after primary treatment (radical prostatectomy, radiotherapy, HIFU, cryotherapy, or brachytherapy)
  • Evaluating the potential value of dynamic MRI in the assessment of local relapse of prostate cancer
  • Evaluating the potential value of dynamic total-body MRI in the assessment of bone involvement of prostate cancer
  • Assessing the actual role of PET/CT in the detection of prostate cancer relapse
  • Evaluating the potential role of new radiotracers for PET/CT
  • Assessing the effect of androgen deprivation therapy on the results of PET/CT
  • Evaluating the value of the imaging-guided salvage treatments for disease relapse of prostate cancer

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/molecular.imaging/rpc/ according to the following timetable:

Manuscript DueFriday, 16 March 2014
First Round of ReviewsFriday, 8 August 2014
Publication DateFriday, 3 October 2014

Lead Guest Editor

  • Riccardo Schiavina, Department of Urology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

Guest Editors

  • Vincenzo Scattoni, Department of Urology, University Vita-Salute, Scientific Institute H San Raffaele, Milan, Italy
  • Paolo Castellucci, Department of Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
  • Mohsen Farsad, PET/CT Unit, Nuclear Medicine Department, Central Hospital, Via Lorenz Böhler, Bolzano, Italy
  • Giampiero Giovacchini, Department of Radio-Oncology and Nuclear Medicine, Stadtspital Triemli, Zurich, Switzerland
  • Eugenio Brunocilla, Department of Urology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy